Search

Smart Rings (SRs) are user-friendly devices capable of measuring various health parameters, making them suitable for remote continuous monitoring in diverse clinical settings. Since the available evidence on the accuracy of SRs recording health data is highly heterogeneous, this systematic review, conducted in accordance with PRISMA guidelines, searched for articles evaluating the efficacy of SRs for sleep, respiratory, and cardiovascular monitoring across the PubMed, SCOPUS, and ProQuest databases. Meta-analyses were conducted for health outcomes evaluated in at least three studies with a comparable study population and design, and the same comparison device. Nineteen articles were included: eleven analyses focused on sleep quality, eight on cardiovascular parameters, and one on oxygen saturation. Studies analysing cardiovascular outcomes found a good accuracy of SRs in measuring heart rate (HR) with a mean bias of −0.4 bpms (limits of agreement (LoAs): −2.7; 1.8). The meta-analyses showed variability in SRs’ efficacy in monitoring total sleep time (mean bias: −21.3 min, LoAs: −69.9, 27.4) and REM duration (mean bias: −18.2 min, LoAs: −33.3, −3.1). The results highlighted the promising potential of SRs for HR monitoring. Further research is needed to clarify the reliability of SRs in monitoring sleep quality and their use directed to a broader range of health parameters. With further development, SRs could become valuable tools for healthcare professionals.

Background: Periodic circadian protein homolog 2 (PER2) has a role in the intracellular signaling pathways of long-term potentiation and has implications for synaptic plasticity. We aimed to assess the association of PER2 C111G polymorphism with cognitive functions in subjective cognitive decline (SCD). Methods: Forty-five SCD patients were included in this study. All participants underwent extensive neuropsychological investigation, analysis of apolipoprotein E (APOE) and PER2 genotypes, and neuropsychological follow-up every 12 or 24 months for a mean time of 9.87 ± 4.38 years. Results: Nine out of 45 patients (20%) were heterozygous carriers of the PER2 C111G polymorphism (G carriers), while 36 patients (80%) were not carriers of the G allele (G non-carriers). At baseline, G carriers had a higher language composite score compared to G non-carriers. During follow-up, 15 (34.88%) patients progressed to mild cognitive impairment (MCI). In this group, we found a significant interaction between PER2 G allele and follow-up time, as carriers of G allele showed greater worsening of executive function, visual-spatial ability, and language composite scores compared to G non-carriers. Conclusions: PER2 C111G polymorphism is associated with better language performance in SCD patients. Nevertheless, as patients progress to MCI, G allele carriers showed a greater worsening in cognitive performance compared to G non-carriers. The effect of PER2 C111G polymorphism depends on the global cognitive status of patients.